Camurus AB
CAMX
Peringkat dalam Saham
#3989
Camurus AB (publ), a biopharmaceutical company, develops and commercializes... Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and phase III clinical trials to treat gastroenteropancreatic neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud’s phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM2056 that is in phase I clinical trials for the treatment of metabolic diseases; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity; and Gubra A/S to develop long-acting therapeutic option for the treatment of hypoparathyroidism; as well as NewBridge Pharmaceuticals. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
Harga Saham
$68.13
Kapitalisasi Pasar
$4.05B
Perubahan (1 hari)
0.82%
Perubahan (1 tahun)
-2.19%
Negara
SE
Perdagangan Camurus AB (CAMX)
Kategori
Healthcare
Margin Operasi untuk Camurus AB (CAMX)
Margin Operasi per October 2026 TTM: 36.33%
Menurut laporan keuangan dan harga saham terbaru dari Camurus AB, margin operasi saat ini (TTM) adalah 36.33%. Pada akhir 2024, margin operasi perusahaan adalah 25.12%.
Riwayat margin operasi untuk Camurus AB dari 2011 hingga 2026
Margin Operasi pada akhir setiap tahun
| Tahun | Margin Operasi | Mengubah |
|---|---|---|
| 2026 (TTM) | 36.33% | -6.92% |
| 2025 | 39.03% | 55.37% |
| 2024 | 25.12% | -18.99% |
| 2023 | 31.01% | 312.37% |
| 2022 | 7.52% | -140.19% |
| 2021 | -18.71% | -69.57% |
| 2020 | -61.48% | -81.97% |
| 2019 | -340.98% | -41.45% |
| 2018 | -582.34% | 29.87% |
| 2017 | -448.41% | 397.79% |
| 2016 | -90.08% | -31.68% |
| 2015 | -131.85% | -540.53% |
| 2014 | 29.93% | -53.52% |
| 2013 | 64.39% | 226.69% |
| 2012 | 19.71% | 0.00% |
| 2011 | 0.00% | 0.00% |
Margin Operasi untuk perusahaan sejenis atau pesaing
| Perusahaan | Margin Operasi | Perbedaan Margin Operasi | Negara |
|---|---|---|---|
| 38.59% | -98.94% |
US
|
|
| -149.01% | -104.10% |
US
|
|
| 25.57% | -99.30% |
AU
|
|
| 28.81% | -99.21% |
NL
|
|
| 0.00% | - |
CH
|
Apa itu Margin Operasi perusahaan?
Margin Operasi adalah indikator utama untuk menilai profitabilitas suatu perusahaan. Margin Operasi yang lebih tinggi umumnya lebih baik karena menunjukkan bahwa perusahaan mampu menjual produk atau layanan mereka dengan harga yang jauh lebih tinggi daripada biaya produksinya. Margin Operasi dihitung dengan membagi laba perusahaan dengan pendapatannya.